The estimated Net Worth of Michael Rosenblatt is at least $791 Tisíc dollars as of 12 November 2021. Michael Rosenblatt owns over 2,831 units of Rubius Therapeutics Inc stock worth over $419 and over the last 15 years he sold RUBY stock worth over $481,502. In addition, he makes $309,285 as Independent Director at Rubius Therapeutics Inc.
Michael has made over 6 trades of the Rubius Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 2,831 units of RUBY stock worth $323,102 on 12 November 2021.
The largest trade he's ever made was exercising 15,000 units of Rubius Therapeutics Inc stock on 19 February 2013 worth over $1,245. On average, Michael trades about 1,230 units every 123 days since 2010. As of 12 November 2021 he still owns at least 5,051 units of Rubius Therapeutics Inc stock.
You can see the complete history of Michael Rosenblatt stock trades at the bottom of the page.
Dr. Michael Rosenblatt is Independent Director of the Company. Dr. Rosenblatt serves on the board of directors of Brooks Automation Inc. and has served on the boards of directors of Radius Health, Inc. and ProScript. Dr. Rosenblatt received an M.D. from Harvard Medical School and an A.B. in chemistry from Columbia University. Rosenblatt's extensive medical and scientific knowledge and his experience in clinical development and executive management in the pharmaceutical industry qualify him to serve as a member of our board of directors.
As the Independent Director of Rubius Therapeutics Inc, the total compensation of Michael Rosenblatt at Rubius Therapeutics Inc is $309,285. There are 13 executives at Rubius Therapeutics Inc getting paid more, with Pablo Cagnoni having the highest compensation of $1,721,130.
Michael Rosenblatt is 69, he's been the Independent Director of Rubius Therapeutics Inc since 2014. There are no older and 18 younger executives at Rubius Therapeutics Inc.
Michael's mailing address filed with the SEC is C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over $2,165,279 worth of Rubius Therapeutics Inc stock and bought 305,000 units worth $6,624,680 . The most active insiders traders include Noubar Afeyan, Roger Pomerantz a Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $2,709. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth $1,350.
developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.
Rubius Therapeutics Inc executives and other stock owners filed with the SEC include: